Stock Hero Advertisement
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator
Search This Board:
Last Post: 5/1/2015 4:18:23 PM - Followers: 36 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for GALT
GALT News: RedChip Announces Presentation Schedule for Its April 22-23 Online Investor Conference 04/15/2015 11:30:59 AM
GALT News: Proxy Statement (definitive) (def 14a) 04/08/2015 04:31:54 PM
GALT News: Galectin Therapeutics Presented Research With GR-MD-02 at the American Association for the Study of Liver Diseases Industry C... 03/24/2015 08:00:00 AM
GALT News: Galectin Therapeutics net loss improves in FY14 03/19/2015 06:38:28 AM
GALT News: Galectin Therapeutics Reports 2014 Financial Results, Provides Business Update 03/18/2015 04:15:00 PM
PostSubject
#1926   Tom: Most definitely. I am holding Tesla1 05/01/15 04:18:23 PM
#1925   Thanks tesla. I suppose I shall just 123tom 05/01/15 03:58:18 PM
#1924   Tom: There continues to be a disconnect Tesla1 05/01/15 03:39:12 PM
#1923   GALT drops to 2.83 now 123tom 05/01/15 02:26:18 PM
#1922   A change in management might do the trick... thefamilyman 04/28/15 05:45:40 PM
#1921   It's frustrating to watch it fizzle like this. Darwinian 04/28/15 05:17:10 PM
#1920   my own plan was (still is) to sell 123tom 04/28/15 05:11:37 PM
#1919   Count on it. That's what happens when you thefamilyman 04/28/15 04:50:24 PM
#1918   Crunch time now for GALT hitting 3 dollar 123tom 04/28/15 02:58:56 PM
#1917   i don t know if this s gonna oldsport 04/27/15 12:59:04 PM
#1916   We sure could use some good news right jmh0602 04/27/15 12:54:45 PM
#1915   awesome oldsport 04/14/15 06:34:00 PM
#1914   "Does anybody know how much it is costing zest 04/14/15 05:58:06 PM
#1913   good job oldsport 04/14/15 05:44:40 PM
#1912   I don't consider truth to be "bashing". thefamilyman 04/14/15 04:22:12 PM
#1910   What? Is there news? Darwinian 04/14/15 02:56:35 PM
#1908   This is a P2a trial. My mistake. IRAHopeful 04/10/15 04:04:34 PM
#1907   Can somebody please tell me how being critical thefamilyman 04/09/15 06:47:03 PM
#1906   anyone take a look at the options for oldsport 04/09/15 02:45:51 PM
#1905   capital loss aside... i am back in the game... oldsport 04/09/15 12:14:29 PM
#1902   sounds like awesome plan ... oldsport 04/08/15 06:03:53 PM
#1901   GALT didn't invent this trial out of thin biotech2010 04/08/15 05:47:17 PM
#1900   There is published research regarding the association between Tesla1 04/08/15 05:20:50 PM
#1899   inflammatory dz are difficult in general and psoriasis oldsport 04/08/15 03:50:26 PM
#1898   My guess on the unannounced trial is that IRAHopeful 04/08/15 03:24:56 PM
#1897   Most early stage biotechs try to "operate" in thefamilyman 04/06/15 01:32:58 AM
#1896   Seemed really odd to me too. It's so Darwinian 04/05/15 09:46:08 PM
#1895   It looks like good news! And it probably thefamilyman 04/05/15 12:36:02 AM
#1894   Someone else posted about this on another message Darwinian 04/04/15 10:33:09 PM
#1893   ichimoku has failed to predict galt for me oldsport 04/01/15 09:45:47 AM
#1892   Good eye last week Old Sport... 123tom 04/01/15 05:14:22 AM
#1891   GALT chart again....3 weeks later 123tom 04/01/15 12:59:10 AM
#1890   I had some angst over the way the Darwinian 03/27/15 10:53:11 AM
#1889   Poor baby, I have hurt your feelings. Let's zest 03/27/15 10:33:35 AM
#1888   what history are you talkin about ? ... oldsport 03/27/15 10:24:00 AM
#1887   You are obviously clueless about GALT's history and biotech2010 03/27/15 10:14:47 AM
#1886   "Due to the gross mismanagement of Platt" zest 03/27/15 02:26:46 AM
#1885   I am NOT "jumping all over the difference thefamilyman 03/27/15 12:48:22 AM
#1884   You are taking my comments way out of contexr. biotech2010 03/27/15 12:12:05 AM
#1883   Thank you for the information. And I had thefamilyman 03/26/15 09:25:48 PM
#1882   familyman, Traber and Czirr are very close friends biotech2010 03/26/15 07:50:45 PM
#1881   I understand that I am apparently in the thefamilyman 03/26/15 04:19:08 PM
#1880   Thanks, I've been curious about genfit's trial for Darwinian 03/26/15 02:34:45 PM
#1879   Genfit announced tepid results which is benefiting ICPT jmh0602 03/26/15 02:13:45 PM
#1878   That's just his salary. sunspotter 03/25/15 01:00:08 PM
#1877   On May 14, 2014, the Compensation Committee and jmh0602 03/25/15 12:43:17 PM
#1876   You are sooo wrong, Galt it is paying zest 03/25/15 12:08:27 AM
#1875   Then GALT needs to open the wallet and thefamilyman 03/24/15 09:17:58 PM
#1874   common man, be fair... traber only gets $200k oldsport 03/24/15 08:51:47 PM
#1873   Traber is also responsible for deceiving investors and thefamilyman 03/24/15 07:49:05 PM
PostSubject